NCNaofumi Chinen

Naofumi Chinen

*This is an algorithmically generated author record based on publicly available information.

Naofumi Chinen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis

    by Yoshitaka Ueda, Naofumi Chinen, Kota Shimada, Naoto Yokogawa

    Introduction Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) can be refractory to treatment, and a triple combination therapy (TCT) consisting of a glucocorticoid, cyclophosphamide, and a calcineurin inhibitor is widely used in induction therapy. For progressive or severe disease despite TCT, another immunosuppressive agent, such as a Janus kinase (JAK) inhibitor, may be added to the induction regimen. Method A retrospective cohort study across two centers in Japan was undertaken between January 2016 and December 2024 evaluating patients with MDA5-DM receiving TCT or quadruple combination therapy (QCT) determining the presence of severe infection. The latter therapy consisted of the addition of a JAK inhibitor to the TCT. A severe infection was defined as Grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Results There were 24 patients were included; TCT: n = 19 and QCT: n = 5. In the former, three (3/19, 16%), two (2/19, 11%), and three (3/19, 16%) patients had a severe bacterial infection, invasive fungal infection, and a CMV infection, respectively. In the QCT group, two (2/5, 40%), two (2/5, 40%), and four (4/5: 80%) patients had a severe bacterial infection, invasive fungal infection, and a CMV infection, respectively. CMV infections were significantly more frequent in the QCT group (p = 0.014). Both TCT and QCT groups had five patients each with a severe infection (5/19, 26% and 5/5, 100%, respectively) (p = 0.006). Conclusion While both TCT and QCT have infection, the QCT group may be at a higher risk, hence highlighting the need for vigilance and adequate prophylaxis. Key Points • The indications for QCT containing a JAK inhibitor should be reviewed carefully in view of an increased risk of infection.


  • Open Access

    Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report

    by Takuya Kakutani, Takahiro Nunokawa, Naofumi Chinen, Yotaro Tamai

    Rationale: Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome are nonmalignant but life-threatening systemic inflammatory disorders. However, many patients are refractory to treatment, resulting in significant morbidity and mortality. Additionally, established treatment options are unavailable. Therefore, we present 2 cases of adults with the iMCD-TAFRO syndrome refractory to initial treatment but responded to Janus kinase (JAK) inhibitors with ruxolitinib. The report reveals that these rare adult cases of the refractory and treatment-resistant iMCD-TAFRO syndrome can be treated using JAK inhibitors. Patient concerns: Case 1 is a 36-year-old previously healthy male patient who presented with fever and general fatigue for 2 weeks. Case 2 is a 42-year-old previously healthy female patient who presented with fever and general fatigue. Diagnosis: The diagnosis met the 2015 criteria for TAFRO syndrome, as determined by All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. Interventions: Treatment with tocilizumab and several immunosuppressants were ineffective. So, we performed ruxolitinib. Outcomes: Each patient received ruxolitinib, the general condition improved, and CRP levels decreased. Lessons: These cases showed that ruxolitinib was effective for treatment-resistant/ refractory TAFRO syndrome. Further prospective studies are needed on using ruxolitinib with a small number of cases.


  • Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study

    by Takahiro Nunokawa, Naofumi Chinen, Kota Shimada, Makiko Kimura, Mutsuto Tateishi, Fang Yi Chen, Keigo Setoguchi, Makoto Sugihara


  • Granulomatous vasculitis presenting as annular erythema in neurosarcoidosis

    by Kei Karakida, Takahiro Nunokawa, Naofumi Chinen, Akio Komatsu

    A 42-year-old woman presented with a 2-month history of annular erythema on the legs ( Fig. 1A) accompanied by ankle pain. Computed tomography revealed bilateral hilar lymphadenopathy, and Löfgren’s syndrome (LS) was suspected, but aseptic meningitis, unilateral facial palsy, and hypoalgesia of the trigeminal nerve and fourth thoracic spinal nerve developed. Skin biopsy revealed epithelioid granuloma and necrotizing vasculitis ( Fig. 1B). Neurosarcoidosis was diagnosed and she received methylprednisolone pulse therapy followed by high-dose prednisolone, which quickly alleviated her symptoms. Cutaneous sarcoidosis is categorized into specific or non-specific types depending on the presence of sarcoid granulomas [ 1]. The most common non-specific type is erythema nodosum, which often presents as part of LS with hilar adenopathy and periarthritis involving the ankles. While LS is usually self-limiting, some specific cutaneous lesions can indicate specific systemic features. Annular erythema is a rare form of cutaneous sarcoidosis, and there are...


  • Open Access

    A Case of Dermatomyositis and Anti-EJ Autoantibody with Chronic Intestinal Pseudoobstruction Successfully Treated with Octreotide

    by Chiho Yamada, Shinji Sato, Noriko Sasaki, Takayoshi Kurabayashi, Sho Sasaki, Yasushi Koyama, Naofumi Chinen, Takayuki Wakabayashi, Yasuo Suzuki

    Chronic intestinal pseudoobstruction (CIPO) is a serious complication in patients with connective tissue disease (CTD) and is sometimes life-threatening or fatal despite intensive medical treatment. Here, we report a patient with dermatomyositis (DM) and anti-EJ autoantibody who developed CIPO that was improved by octreotide. Because her abdominal pain and bloatedness were so severe and persistent, we introduced octreotide to relieve symptoms. In this case, continuous intravenous administration as well as long-acting subcutaneous injection of octreotide was effective for treating CIPO.


  • Open Access

    A Case of Acute Budd-Chiari Syndrome Complicating Primary Antiphospholipid Syndrome Presenting as Acute Abdomen and Responding to Tight Anticoagulant Therapy

    by Naofumi Chinen, Yasushi Koyama, Shinji Sato, Yasuo Suzuki

    A 34-year-old woman with primary antiphospholipid syndrome was admitted to the Gastroenterology Department of our hospital with fever, acute abdomen, watery diarrhea, and extremely high levels of inflammatory parameters. She had a history of left lower limb deep vein thrombosis and pulmonary embolism and was taking warfarin potassium. Acute gastroenteritis was suspected and an antibiotic was administered, but symptoms progressed. Abdominal ultrasonography showed occlusion of the left hepatic vein and the middle hepatic vein and her D-dimer level was high. Accordingly, Budd-Chiari syndrome was diagnosed and high-dose intravenous infusion of heparin was initiated. Her abdominal symptoms improved and the levels of inflammatory parameters and D-dimer decreased rapidly. It is known that antiphospholipid syndrome can be complicated by Budd-Chiari syndrome that usually occurs as subacute or chronic onset, but acute onset is rare. It is difficult to diagnose acute Budd-Chiari syndrome complicating antiphospholipid syndrome and this complication generally has a poor outcome. However, the present case can get early diagnosis and successful treatment with tight anticoagulant therapy.